Skip to main content
SpringerLink
Log in

Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hypothyroidism

  • Original Paper
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

Various abnormalities of coagulation–fibrinolytic system have been reported in patients with thyroid dysfunction. Several studies indicate that coagulation and fibrinolytic system is disturbed in the patients with hypothyroidism. Also, the influence of hypothyroidism on hemostasis is controversial; both hypocoagulable and hypercoagulable states have been reported. The levels of plasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and tissue factor pathway inhibitor (TFPI) have been investigated only once in patients with hypothyroidism. Therefore, the main purpose of this study was to evaluate the profile of coagulation and fibrinolytic parameters including TAFI and TFPI in patients with hypothyroidism. Fifteen patients with untreated hypothyroidism and 15 age-matched healthy controls were included in the study. Factors V(FV), VII (FVII), VIII (FVIII) activities, von Willebrand factor (vWF), protein C, protein S, thrombomodulin (TM), TFPI, and TAFI were measured. The relationships between serum thyroid hormones and these hemostatic parameters were examined. Compared with the control subjects, FVII activity, and TM Ag and TAFI Ag levels were significantly increased in patients with hypothyroidism, whereas FV, FVIII, vWF, protein C and protein S activities, and TFPI Ag levels were significantly decreased. We did not find any significant correlation between serum thyroid hormones and the hemostatic parameters that we measured. In conclusion, we found some important differences in the hemostatic parameters between the patients with hypothyroidism and healthy controls. Increased FVII, TM, and TAFI and decreased FV, FVIII, vWF, protein C, protein S, and TFPI in these patients represent a potential hypercoagulable and hypofibrinolytic state, possible endothelial dysfunction, which might augment the risk for atherosclerotic and atherothrombotic complications. Thus, disturbances of the hemostatic system may contribute to the excess mortality due to cardiovascular disease seen in patients with hypothyroidism.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. C. Erem, H.Ö. Ersoz, S.S. Kartı, K. Ukinç, A. Hacıhasanoğlu, O. Değer, M. Telatar, Blood coagulation and fibrinolysis in patients with hyperthyroidism. J. Endocrinol. Invest. 25, 345–350 (2002)

    CAS  PubMed  Google Scholar 

  2. C. Erem, H. Kavgacı, H.Ö. Ersoz, A. Hacıhasanoğlu, K. Ukinç, S.S. Kartı, O. Değer, M. Telatar, Blood coagulation and fibrinolytic activity in hypothyroidism. Int. J. Clin. Pract. 57, 78–81 (2003)

    CAS  PubMed  Google Scholar 

  3. C. Erem, Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity. Clin. Endocrinol. 64, 323–329 (2006)

    Article  CAS  Google Scholar 

  4. A. Squizzato, E. Romualdi, H.R. Büller, V.E. Gerdes, Clinical review: thyroid dysfunction and effects on coagulation and fibrinolysis:a systematic review. J. Clin. Endocrinol. Metab. 92, 2415–2420 (2007)

    Article  CAS  PubMed  Google Scholar 

  5. M. Franchini, Hemostasis and thyroid diseases revisited. J. Endocrinol. Invest. 27, 886–892 (2004)

    CAS  PubMed  Google Scholar 

  6. F. Marongiu, C. Cauli, S. Mariotti, Thyroid, hemostasis and thrombosis. J. Endocrinol. Invest. 27, 1065–1071 (2004)

    CAS  PubMed  Google Scholar 

  7. S. Gullu, H. Sav, N. Kamel, Effects of levothyroxine treatment on biochemical and hemostasis parameters in patients with hypothyroidism. Eur. J. Endocrinol. 152, 355–361 (2005)

    Article  CAS  PubMed  Google Scholar 

  8. B. Myrup, C. Bregengård, J. Faber, Primary haemostasis in thyroid disease. J. Intern. Med. 238, 59–63 (1995)

    Article  CAS  PubMed  Google Scholar 

  9. M. Franchini, Hemostatic changes in thyroid diseases. Hematology 11, 203–208 (2006)

    Article  CAS  PubMed  Google Scholar 

  10. M.A. Ozcan, A. Comlekci, F. Demirkan, F. Yuksel, I. Sari, T. Demir, G.H. Ozsan, G. Oruk, S. Yesil, B. Undar, Plasma levels of free tissue factor pathway inhibitor in patients with various thyroid disorders. Thromb. Res. 110, 243–247 (2003)

    Article  CAS  PubMed  Google Scholar 

  11. F. Marongiu, G. Biondi, M. Conti, M.L. Murtas, G. Mameli, G.G. Sorano, E. Martino, Is a hypercoagulable state present in hypothyroidism? Thromb. Haemost. 67, 729 (1992)

    CAS  PubMed  Google Scholar 

  12. R. Chadarevian, E. Bruckert, A. Ankri, I. Beucler, P. Giral, G. Turpin, Relationship between thyroid hormones and plasma D-dimer levels. Thromb. Haemost. 79, 99–103 (1998)

    CAS  PubMed  Google Scholar 

  13. R. Chadarevian, E. Bruckert, L. Leenhardt, P. Giral, A. Ankri, G. Turpin, Components of the fibrinolytic system are differently altered in moderate and severe hypothyroidism. Clin. Endocrinol. Metab. 86, 732–737 (2001)

    Article  CAS  Google Scholar 

  14. B. Müller, D.A. Tsakiris, C.B. Roth, M. Guglielmetti, J.J. Staub, G.A. Marbet, Haemostatic profile in hypothyroidism as potential risk factor for vascular or thrombotic disease. Eur. J. Clin. Invest. 31, 131–137 (2001)

    Article  PubMed  Google Scholar 

  15. E. Rooth, H. Wallen, A. Antovic, M. von Arbin, G. Kaponides, N. Wahlgren, M. Blombäck, J. Antovic, Thrombin activatable fibrinolysis inhibitor and its relationship to fibrinolysis and inflammation during the acute and convalescent phase of ischemic stroke. Blood Coagul. Fibrinolysis 18, 365–370 (2007)

    Article  CAS  PubMed  Google Scholar 

  16. A. Redlitz, A.K. Tan, D.L. Eaton, E.F. Plow, Plasma carboxypeptidases as regulators of the plasminogen system. J. Clin. Invest. 96, 2534–2538 (1995)

    Article  CAS  PubMed  Google Scholar 

  17. N.H. van Tilburg, F.R. Rosendaal, R.M. Bertina, Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 95, 2855–2859 (2000)

    PubMed  Google Scholar 

  18. S. Eichinger, V. Schönauer, A. Weltermann, E. Minar, C. Bialonczyk, M. Hirschl, B. Schneider, P. Quehenberger, P.A. Kyrle, Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood 103, 3773–3776 (2004)

    Article  CAS  PubMed  Google Scholar 

  19. F.W. Leebeek, M.P. Goor, A.H. Guimaraes, G.J. Brouwers, M.P. Maat, D.W. Dippel, D.C. Rijken, High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke. J. Thromb. Haemost. 3, 2211–2218 (2005)

    Article  CAS  PubMed  Google Scholar 

  20. J. Montaner, M. Ribó, J. Monasterio, C.A. Molina, J. Alvarez-Sabín, Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischemic stroke. Stroke 34, 1038–1040 (2003)

    Article  CAS  PubMed  Google Scholar 

  21. T.M. Ravindranath, M. Goto, O. Iqbal, M. Florian-Kujawski, D. Hoppensteadt, R. Hammadeh, M.M. Sayeed, J. Fareed, Plasma thrombin activatable fibrinolysis inhibitor and tissue factor pathway inhibitor changes following sepsis. Clin. Appl. Thromb. Hemost. 13, 362–368 (2007)

    Article  CAS  PubMed  Google Scholar 

  22. G.J. Broze Jr., The role of tissue factor pathway inhibitor in a revised coagulation cascade. Semin. Hematol. 29, 159–169 (1992)

    CAS  PubMed  Google Scholar 

  23. T. Abumiya, T. Yamaguchi, T. Terasaki, T. Kokawa, K. Kario, H. Kato, Decreased plasma tissue factor pathway inhibitor activity in ischemic stroke patients. Thromb. Haemost. 74, 1050–1054 (1995)

    CAS  PubMed  Google Scholar 

  24. M. Kobayashi, H. Wada, Y. Wakita, M. Shimura, T. Nakase, K. Hiyoyama, S. Nagaya, N. Minami, T. Nakano, H. Shiku, Decreased plasma tissue factor pathway inhibitor levels in patients with thrombotic thrombocytopenic purpura. Thromb. Haemost. 73, 10–14 (1995)

    CAS  PubMed  Google Scholar 

  25. G.M. Harris, C.L. Stendt, B.J. Vollenhoven, T.E. Gan, P.G. Tipping, Decreased plasma tissue factor pathway inhibitor in women taking combined oral contraceptives. Am. J. Hematol. 60, 175–180 (1999)

    Article  CAS  PubMed  Google Scholar 

  26. B. Akinci, A. Comlekci, M. Ali Ozcan, T. Demir, S. Yener, F. Demirkan, F. Yuksel, S. Yesil, Elevated thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels in overt and subclinical hypothyroid patients were reduced by levothyroxine replacement. Endocr. J. 54, 45–52 (2007)

    Article  CAS  PubMed  Google Scholar 

  27. R. Jorde, Y. Figenschau, J.B. Hansen, Haemostatic function in subjects with mild subclinical hypothyroidism. The Tromsø study. Thromb. Haemost. 95, 750–751 (2006)

    CAS  Google Scholar 

  28. L.C. Hofbauer, A.E. Heufelder, Coagulation disorders in thyroid diseases. Eur. J. Endocrinol. 136, 1–7 (1997)

    Article  CAS  PubMed  Google Scholar 

  29. M. Homoncik, A. Gessl, A. Ferlitsch, B. Jilma, H. Vierhapper, Altered platelet plug formation in hyperthyroidism and hypothyroidism. J. Clin. Endocrinol. Metab. 92, 3006–3012 (2007)

    Article  CAS  PubMed  Google Scholar 

  30. R.G. Dalton, M.S. Dewar, G.F. Savidge, P.B. Kernoff, K.B. Matthews, M. Greaves, F.E. Preston, Hypothyroidism as a cause of acquired von Willebrand’s disease. Lancet 1, 1007–1009 (1987)

    Article  CAS  PubMed  Google Scholar 

  31. S.R. Smith, M.J. Anger, Hypothyroidism and von Willebrand’s disease. Lancet 1, 1314 (1987)

    Article  Google Scholar 

  32. J.J. Michiels, W. Schroyens, Z. Berneman, M. van der Planken, Acquired von Willebrand syndrome type 1 in hypothyroidism: reversal after treatment with thyroxine. Clin. Appl. Thromb. Hemost. 7, 113–115 (2001)

    Article  CAS  PubMed  Google Scholar 

  33. M.L. Tachman, G.P. Guthrie Jr., Hypothyroidism: diversity of presentation. Endocr. Rev. 5, 456–465 (1984)

    Article  CAS  PubMed  Google Scholar 

  34. D. Feinbloom, K.A. Bauer, Assessment of hemostatic risk factors in predicting arterial thrombotic events. Arterioscler. Thromb. Vasc. Biol. 25, 2043–2053 (2005)

    Article  CAS  PubMed  Google Scholar 

  35. T.W. Meade, S. Mellows, M. Brozovic, G.J. Miller, R.R. Chakrabarti, W.R. North et al., Haemostatic function and ischaemic heart disease: principal results of the Northwick Park heart study. Lancet 2, 533–537 (1986)

    Article  CAS  PubMed  Google Scholar 

  36. R. Junker, J. Heinrich, H. Schulte, J. van de Loo, G. Assmann, Coagulation factor VII and the risk of coronary heart disease in healthy men. Arterioscler. Thromb. Vasc. Biol. 17, 1539–1544 (1997)

    CAS  PubMed  Google Scholar 

  37. P. Broadhurst, C. Kelleher, L. Hughes, J.D. Imeson, E.B. Raftery, Fibrinogen, factor VII clotting activity and coronary artery disease severity. Atherosclerosis 85, 169–173 (1990)

    Article  CAS  PubMed  Google Scholar 

  38. V. Ruddock, T.W. Meade, Factor VII activity and ischaemic heart disease: fatal and non-fatal events. QJM 87, 403–406 (1994)

    CAS  PubMed  Google Scholar 

  39. B. Dahlback, B.O. Villoutreix, The anticoagulant protein C pathway. FEBS Lett. 579, 3310–3316 (2005)

    Article  PubMed  Google Scholar 

  40. M.L. Moster, Coagulopathies and arterial stroke. J. Neuroophthalmol. 23, 63–71 (2003)

    PubMed  Google Scholar 

  41. B. Dahlbäck, Blood coagulation. Lancet 355, 1627–1632 (2000)

    Article  PubMed  Google Scholar 

  42. Y. Morikawa, A. Morikawa, I. Makino, Relationship of thyroid states and serum thrombomodulin (TM) levels in patients with Graves’ disease: TM, a possible new marker of the peripheral activity of thyroid hormones. J. Clin. Endocrinol. Metab. 76, 609–614 (1993)

    Article  CAS  PubMed  Google Scholar 

  43. M. Soma, Y. Maeda, R. Matsuura, I. Sasaki, S. Kasakura, Y. Saeki, K. Ikekubo, T. Ishihara, H. Kurahachi, S. Sasaki, T. Tagami, K. Nakao, Study of serum Thrombomodulin (TM) levels in patients with hyper-or hypo-thyroidism. Rinsho Byori 45, 77–81 (1997)

    CAS  PubMed  Google Scholar 

  44. T. Nagasaki, M. Inaba, Y. Hiura, H. Tahara, Y. Kumeda, K. Shirakawa, N. Onoda, T. Ishikawa, E. Ishimura, Y. Nishizawa, Plasma levels of adiponectin and soluble thrombomodulin in hypothyroid patients with normal thyroid function following levothyroxine replacement therapy. Biomed. Pharmacother. 59, 571–577 (2005)

    Article  CAS  PubMed  Google Scholar 

  45. B.A. Lwaleed, P.S. Bass, Tissue factor pathway inhibitor: structure, biology and involvement in disease. J. Pathol. 208, 327–339 (2006)

    Article  CAS  PubMed  Google Scholar 

  46. M. Hoke, P.A. Kyrle, E. Minar, C. Bialonzcyk, M. Hirschl, B. Schneider, M. Kollars, A. Weltermann, S. Eichinger, Tissue factor pathway inhibitor and the risk of recurrent venous thromboembolism. Thromb. Haemost. 94, 787–790 (2005)

    PubMed  Google Scholar 

  47. J. Monasterio, P. Bermúdez, D. Quiroga, E. Francisco, B. Meneses, J. Montaner, Plasma thrombin-activatable fibrinolytic inhibitor (TAFI) among healthy subjects and patients with vascular diseases: a validation study. Pathophysiol. Haemost. Thromb. 33, 382–386 (2003)

    Article  CAS  PubMed  Google Scholar 

  48. L. Bajzar, R. Manuel, M.E. Nesheim, Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J. Biol. Chem. 270, 14477–14484 (1995)

    Article  CAS  PubMed  Google Scholar 

  49. I. Juhan-Vague, P.E. Morange, H. Aubert, M. Henry, M.F. Aillaud, M.C. Alessi, A. Samnegård, E. Hawe, J. Yudkin, M. Margaglione, G. Di Minno, A. Hamsten, S.E. Humphries, HIFMECH Study Group. Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe. Arterioscler. Thromb. Vasc. Biol. 22, 867–873 (2002)

    Article  CAS  PubMed  Google Scholar 

  50. A. Silveira, K. Schatteman, F. Goossens, E. Moor, S. Scharpé, M. Strömqvist, D. Hendriks, A. Hamsten, Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb. Haemost. 84, 364–368 (2000)

    CAS  PubMed  Google Scholar 

  51. V. Schroeder, T. Chatterjee, H. Mehta, S. Windecker, T. Pham, N. Devantay, B. Meier, H.P. Kohler, Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography. Thromb. Haemost. 88, 1020–1025 (2002)

    CAS  PubMed  Google Scholar 

  52. H.K. Lau, A. Segev, R.A. Hegele, J.D. Sparkes, J.M. Teitel, R.J. Chisholm, B.H. Strauss, Thrombin-activatable fibrinolysis inhibitor (TAFI): a novel predictor of angiographic coronary restenosis. Thromb. Haemost. 90, 1187–1191 (2003)

    CAS  PubMed  Google Scholar 

  53. A. Santamaría, A. Martínez-Rubio, M. Borrell, J. Mateo, R. Ortín, J. Fontcuberta, Risk of acute coronary artery disease associated with functional thrombin activatable fibrinolysis inhibitor plasma level. Haematologica 89, 880–881 (2004)

    PubMed  Google Scholar 

Download references

Acknowledgment

This study was supported by a research grant from the Karadeniz Technical University (Project No. 2005.114.003.2).

Author information

Authors and Affiliations

  1. Division of Endocrinology and Metabolism, Department of Internal Medicine, Karadeniz Technical University, Faculty of Medicine, 61080, Trabzon, Turkey

    Cihangir Erem, Ozge Ucuncu, Mustafa Kocak, İrfan Nuhoglu & Halil Onder Ersoz

  2. Division of Hematology, Department of Internal Medicine, Karadeniz Technical University, Faculty of Medicine, 61080, Trabzon, Turkey

    Mustafa Yilmaz

Authors
  1. Cihangir Erem
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ozge Ucuncu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mustafa Yilmaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mustafa Kocak
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. İrfan Nuhoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Halil Onder Ersoz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cihangir Erem.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Erem, C., Ucuncu, O., Yilmaz, M. et al. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hypothyroidism. Endocr 35, 75–80 (2009). https://doi.org/10.1007/s12020-008-9116-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-008-9116-4

Keywords

Search

Navigation